Meet Cromos Pharma at World Orphan Drug Congress 2023!
Cromos Pharma is delighted to be taking part in World Orphan Drug Congress 2023 which will take place May 23-25 in Washington D.C.
Nicole Brenna, US Business Development Director, is looking forward to meeting partners and potential clients to hear about their clinical program plans. Reach out to us directly at email@example.com to set up a meeting to discuss your clinical programs.
The World Orphan Drug Congress brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The conference is a place to get together and discuss how to improve access to life-saving therapies and advance the development of orphan drugs.
At Cromos Pharma we have built up extensive expertise in orphan drug research and developed solutions to overcome some of key challenges in this area. Our expert team has contributed to the analysis, design, management and/or conduct of 20+ studies in rare diseases, covering Phases I to IV.
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye resulting in rapid patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.